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This study aimed to identify the clinical characteristics of culture-positive pulmonary tuberculosis
(TB) patients from a southern Taiwan hospital-based survey between August 1, 2003 and July 31,
2006. Demographics, symptoms, susceptibility patterns, sputum acid-fast bacilli (AFB) stain status
and treatment outcomes were recorded. The medical records of 154 patients who presented to the
Kaohsiung Municipal Hsiao-Kang Hospital were analyzed retrospectively. The mean age of patients
was 59.5 years; 115 patients were male and 39 were female. Diabetes mellitus (48/154; 31.2%) was
the most frequent risk factor for pulmonary TB infection. Nearly all patients (139/154; 90.3%) had
a cough. Fever was only seen in 27.9% and hemoptysis in 14.9% of patients. The combined resistance
rates of Mycobacterium tuberculosis to the tested first-line agents were as follows: isoniazid, 3.2%;
rifampin, 7.8%; ethambutol, 5.8%; and streptomycin, 2.6%. The combined resistance rate to any one
of four first-line drugs was 12.3%. The combined resistance rate to ofloxacin was 3.9%. The com-
bined resistance rate of multidrug resistant-TB was 1.9%. Sputum AFB stains were positive in 68.2%
of cases. Analysis of treatment outcomes showed overall treatment success at 76.6%. The proportions
of patients who died, defaulted treatment or in whom treatment failed were 16.2%, 3.9% and
0.0%, respectively. In conclusion, our study showed: (1) a higher frequency of pulmonary TB in male
subjects than in other areas of Taiwan; (2) a higher frequency of cough and lower frequency of fever
and hemoptysis than previous studies; (3) that the combined resistance rates to isoniazid and
streptomycin were lower than both average levels in Taiwan and the global combined drug resist-
ance rate; and (4) a higher proportion of patients responding to treatment and lower proportions
of patients suffering mortality, defaulting treatment or not responding to treatment compared with
other areas of Taiwan. With regard to resistance rates, the combined resistance rate to ethambutol
was similar to the average level in Taiwan and higher than the global combined drug resistance
rate. However, the combined resistance rate to rifampin was higher than both the average level in
Taiwan and the global combined drug resistance rate. The combined resistance rates to at least
any one of four first-line drugs and multidrug resistant-TB were lower than the average levels in
Taiwan and higher than the global combined drug resistance rate. Our results may help to identify
local variations in the disease and improve the effectiveness of TB infection control programs.
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Although the prevalence of tuberculosis (TB) has de-
clined significantly in Western countries during the
past several decades, TB remains one of the most
common infectious diseases in developing countries
[1]. In Taiwan, TB has remained the leading notifiable
communicable disease for years. In 2004, the incidence
rate was 74.1 per 100,000 people and the mortality
rate was 4.23 per 100,000 people. TB accounted for
0.72% of the total deaths and TB ranked 13th among
the leading causes of death. Among notifiable com-
municable diseases, TB has remained the number
one killer for years [2].
We believe a description of the clinical character-
istics of pulmonary TB serves two important purposes.
First, it provides a contemporary description that
may be valuable to clinicians, public health officials
and agencies to screen for active TB. Second, a sub-
group analysis will provide insight as to which groups
may present atypically with the disease. In addition,
the epidemiology of pulmonary TB has changed, rais-
ing the question of whether the clinical characteristics
described in the past remain valid today.
Global surveillance of drug resistance has shown
that a substantial proportion of TB patients are infected
with drug-resistant Mycobacterium tuberculosis strains
[3]. In Taiwan, the incidence of drug resistance among
M. tuberculosis isolates and the associated mortality
have remained high despite recent advances in anti-
TB therapy and an understanding of well-known TB
control strategies [2]. Variations in susceptibility data,
due to the use of different methods in studies from
different regions of Taiwan and the lack of a program
for the nationwide surveillance of drug resistance using
a uniform and standard method, has made data on
the resistance patterns in Taiwan unclear [4].
There has been only one previously published
study on the prevalence of drug-resistant TB in south-
ern Taiwan from 1996 to 2000 [5]. However, that 
survey did not precisely distinguish between newly
diagnosed and re-treatment cases, only the combined
resistance rate. Thus, we undertook this study to eval-
uate the prevalence of drug-resistant isolates of pul-
monary TB at Kaohsiung Municipal Hsiao-Kang
Hospital in southern Taiwan in the last 3 years,
including primary (resistance among new cases),
acquired (resistance among re-treatment cases), and
combined (resistance among new and re-treatment
cases) drug resistance. We also present an approach
to the subgroup analysis of treatment outcomes of
pulmonary TB cases from a hospital-based survey
performed in southern Taiwan.
METHODS
This study was conducted at Kaohsiung Municipal
Hsiao-Kang Hospital, which is a 500-bed, university-
affiliated teaching hospital that serves as a tertiary
referral center and a primary-care facility in southern
Taiwan. From a retrospective review, 154 consecutive
adult patients with pulmonary TB detected in the
period from August 1, 2003 to July 31, 2006 were
selected. Cases were identified from the hospital cod-
ing system and microbiology department records.
Patients who were younger than 18 years and those
who were not Taiwanese were excluded. The diag-
nosis of pulmonary TB was based on at least one 
sputum culture that was positive for M. tuberculosis.
Patients included outpatients and inpatients at initial
visit. Re-treatment cases and newly diagnosed cases
were also enrolled in the study. Sputum samples
were obtained by spontaneous morning expectora-
tion, saline solution induction, tracheal aspiration, or
bronchoscopy with bronchoalveolar lavage. Repeated
isolates with the same antibiogram from the same pa-
tient during the same diagnosis course were regarded
as one strain. This study was reviewed and approved
by the human experiment and ethics committee of
Kaohsiung Municipal Hsiao-Kang Hospital.
All patients had a medical chart and microbiology
results. Patients were interviewed by the same trained
nurse case manager using a structured questionnaire
and the completed questionnaires were then reviewed
by the physician investigator. Demographic informa-
tion included age, sex and body mass index. We
recorded risk factors for TB infection, including a his-
tory of TB infection, exposure to an individual with
TB, alcoholism, substance abuse, long-term glucos-
teroid medication, immunosuppressive drug use and
other comorbidities, such as diabetes mellitus, end-
stage renal disease, cancer, human immunodeficiency
virus infection, silicosis and post-gastrectomy. Clinical
symptoms included the presence of cough, expecto-
ration, weight loss, fever, shortness of breath, anorexia,
hemoptysis, chest pain, fatigue and night sweats.
All sputum smears were concentrated and stained
with Ziehl-Neelsen stains by trained microbiology
technicians. Each sputum sample was prepared in
Löwenstein-Jensen culture medium and Middlebrook
7H11 selective agar, and maintained for at least 
8 weeks to detect the presence of growing organisms.
Susceptibility of M. tuberculosis isolates to four first-
line antimicrobial agents, isoniazid, rifampicin, etham-
butol and streptomycin, and one second-line agent,
ofloxacin, was determined by the proportion method
using Middlebrook 7H10 medium. Although this is a
retrospective study, quality control was usually per-
formed during susceptibility testing using a reference
strain provided by the College of American Pathol-
ogists and the national reference laboratory. The 
concentrations of the drugs used were as follows: 
isoniazid, 1 µg/mL; rifampin, 1 µg/mL; ethambutol,
10 µg/mL; streptomycin, 10 µg/mL; and ofloxacin,
2 µg/mL. Tested isolates were considered resistant if
the proportion of the tested isolate was > 1% of the
control population. Drug resistance was defined as
either single or any resistance to anti-TB drugs.
Multidrug resistance (MDR) was defined as resist-
ance towards at least isoniazid and rifampicin. In
patients who had not previously received anti-TB
drugs, the bacterial resistance was classified as pri-
mary. Acquired drug resistance was defined as re-
sistance among re-treatment cases. Combined drug
resistance was defined as resistance among new and
re-treatment cases.
Treatment outcomes were analyzed and defined
according to the World Health Organization (WHO)
recommendations [6]. “Cure” was defined as a patient
who was sputum smear-negative in the last month 
of treatment and on at least one previous occasion.
“Treatment completed” was defined as a patient who
had completed treatment, but who did not meet the
criteria to be classified as a cure or a failure. “Treatment
success” included both of these categories. “Treatment
failure” was defined as a patient who was sputum
smear-positive at 5 months or later during treatment.
“Died” was defined as a patient who died for any
reason during the course of treatment. “Default” was
defined as a patient whose treatment was interrupted
for 2 consecutive months or more. “Transfer out” was
defined as a patient who was transferred to another
recording and reporting unit, and for whom the
treatment outcome was not known.
Statistical analysis
Data in the text and illustrations correspond to 
mean ± standard deviation (continuous variables) or
to frequencies and percentages (non-continuous vari-
ables). All analyses were performed using SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Demographic information
One hundred and fifty-four culture-positive pulmon-
ary TB patients were enrolled in the study. Eighty
outpatients and 74 inpatients at initial visit were
identified. Mean age was 59.5 ± 18 years (range, 20–
91 years). Patients aged ≥ 65 years comprised 42.9%
of the patient group, which was followed by people
aged between 45 and 64 years (36.4%). One hundred
and fifteen patients were male (74.7%) and 39 were
female (25.3%). Demographic information is presented
in Table 1.
Risk factors
Risk factors are depicted in Table 2. Diabetes mellitus
was the most frequent risk factor for pulmonary TB
infection (n = 48, 31.2%). Twenty-one patients were
re-treatment cases (13.6%). No patients had any of
the following risk factors for pulmonary TB infection
in this study: substance abuse, long-term gluco-
steroid medication, immunosuppressive drug use,
human immunodeficiency virus infection, silicosis or
post-gastrectomy.
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Table 1. Demographic information on 154 pulmonary
tuberculosis cases
n (%)
Age (yr)
20–44 32 (20.8)
45–64 56 (36.4)
≥ 65 66 (42.9)
Mean (SD) 59.5 (18.0)
Median (range) 61 (20–91)
Body mass index (kg/m2)
Mean (SD) 20.4 (3.6)
Median (range) 20.6 (14.5–31.4)
Sex
Male 115 (74.7)
Female 39 (25.3)
Patient type
Outpatients 80 (51.9)
Inpatients 74 (48.1)
SD = standard deviation.
Clinical symptoms
Table 3 shows the percentages of patients with each
symptom. The most common presenting symptoms
were cough (90.3%), expectoration (72.1%) and weight
loss (33.1%). Other presenting complaints were fever
(27.9%), shortness of breath (25.3%), anorexia (22.1%),
hemoptysis (14.9%), chest pain (12.3%), fatigue (7.8%)
and night sweats (7.1%).
Drug resistances and sputum acid-fast
bacilli stain status
Drug resistance to M. tuberculosis is shown in Table 4.
The combined resistance rates of M. tuberculosis 
to the tested first-line agents were as follows: isoni-
azid, 3.2%; rifampin, 7.8%; ethambutol, 5.8%; and
streptomycin, 2.6%. The combined resistance rate of
M. tuberculosis to any one of the four first-line drugs
was 12.3%. The combined resistance rate of MDR-TB
was 1.9%. The combined resistance rate of M. tuberculo-
sis to ofloxacin was 3.9%. Of the 154 culture-positive
pulmonary TB patients, 105 were sputum acid-fast
bacilli stain-positive (68.2%).
Outcomes of treatment
The outcomes at the completion of treatment are
summarized in Table 5. Five patients were transferred
out. Successful completion of therapy was achieved
in 76.6% of patients. The proportions of patients who
died, defaulted treatment, or in whom treatment failed
were 16.2%, 3.9% and 0.0%, respectively.
DISCUSSION
In Taiwan, of the TB patients who died in 2003, 95.72%
died of pulmonary TB while the remaining 4.28%
died of TB related to other organs. The incidence rate
increased with age [2]. In the present study, patients
aged ≥ 65 years comprised 42.9% of the study group,
which was followed by people aged between 45 and
64 (36.4%). This increase with age was similar to that
observed in other areas of Taiwan. Since the aging of the
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Table 2. Risk factors in 154 pulmonary tuberculosis
(TB) cases
Risk factor n (%)
History of TB infection 21 (13.6)
History of exposure to an 8 (5.2)
individual with TB
Alcoholism 14 (9.1)
Diabetes mellitus 48 (31.2)
End-stage renal disease 3 (1.9)
Cancer 10 (6.5)
Table 3. Clinical symptoms of 154 pulmonary tubercu-
losis (TB) cases
Symptom n (%)
Cough 139 (90.3)
Expectoration 111 (72.1)
Weight loss 51 (33.1)
Fever 43 (27.9)
Shortness of breath 39 (25.3)
Anorexia 34 (22.1)
Hemoptysis 23 (14.9)
Chest pain 19 (12.3)
Fatigue 12 (7.8)
Night sweats 11 (7.1)
Table 4. Drug resistance of Mycobacterium tuberculosis
isolates recovered from 154 pulmonary tuberculosis
cases*
Primary Acquired Combined
(n = 133) (n = 21) (n = 154)
Resistant to
Isoniazid 4 (3.0) 1 (4.8) 5 (3.2)
Rifampin 7 (5.3) 5 (23.8) 12 (7.8)
Ethambutol 9 (6.8) 0 (0.0) 9 (5.8)
Streptomycin 2 (1.5) 2 (9.5) 4 (2.6)
Any drug† 14 (10.5) 5 (23.8) 19 (12.3)
MDR 2 (1.5) 1 (4.8) 3 (1.9)
Ofloxacin 6 (4.5) 0 (0.0) 6 (3.9)
*Data are presented as n (%); †resistance to any one of four
first-line drugs, specifically: isoniazid, ethambutol, rifampin
and streptomycin. MDR = multidrug resistance.
Table 5. Outcomes at the completion of anti-tuberculosis
treatment
Outcome n (%)
Cure 45 (29.2)
Treatment complete 73 (47.4)
Treatment success* 118 (76.6)
Treatment failure 0 (0.0)
Died 25 (16.2)
Default 6 (3.9)
Transfer out 5 (3.3)
Total 154 (100.0)
*Defined as the sum of patients cured and those who completed
treatment.
general population in Taiwan is expected to continue,
it can also be expected that the caseload of TB will be
increasingly associated with the elderly. The clinical
presentation of disease in the elderly is often atypical
[7,8]. Diagnosis and treatment are more often delayed
in the elderly, and there is a higher incidence of treat-
ment failure [9]. Therefore, physicians should give
greater consideration to TB in the differential diag-
nosis of elderly patients with pulmonary symptoms 
or obscure fever, and promptly investigate suspected
cases to allow earlier diagnosis and treatment.
In Taiwan, with regard to the gender of TB patients,
a previous study showed that there were about 2.29
times more male than female patients, and that the
incidence rate for males was 2.2 times the number for
females in 2004 [2]. In our study, the incidence rate 
in male patients was almost three times higher than
that in female patients. The reason for the higher fre-
quency of TB in male subjects has not been suffi-
ciently addressed. One possible explanation for this
gender difference is that, in most countries, young
men perform more social and labor-related activities
than women, thus favoring the transmission of the
disease. This hypothesis is in agreement with the higher
prevalence of positive tuberculin test results in male
subjects than in female subjects [10,11]. The higher
rates of infection in young men could result in the
higher frequency of the development of symptomatic
TB. However, the presence of a biological factor con-
ferring protection against infection and/or clinical
development of TB in female subjects cannot be pre-
cluded, and deserves further investigation.
In Taiwan, the incidence of TB in patients with
diabetes mellitus was 5.6 times higher than the over-
all incidence (363.0 vs. 64.8 per 100,000 people) in 2001
[12]. In the present study, diabetes mellitus was the
most frequent risk factor for pulmonary TB infection
(31.2%). Similar studies have revealed a higher per-
centage of pulmonary TB in individuals with diabetes
mellitus [13–15].
Differences in the symptom prevalence noted in
the present study might reflect local variations in the
disease. The rate of cough (90.3%) in our study may
also reflect the inclusion in our population of outpa-
tients, a group almost invariably ignored in previous
symptom studies. Although we were unable to find
population-based studies of pulmonary TB, recent
hospital-based studies have demonstrated cough rates
of 50–77% [16–18]. Fever (27.9%) and hemoptysis
(14.9%) rates in our study were surprisingly lower than
expected and than shown in previous studies [19,20],
suggesting that atypical TB presentation may be more
common than previously thought. This finding has
implications for clinicians who we believe should not
dismiss TB as a possibility in those who lack the more
“classical” symptoms of the disease. The surprisingly
low rate of people lacking the typical significant symp-
toms of TB may in part explain the delays in suspi-
cion of TB disease [21,22]. Whether the symptomatic
differences in studies of TB represent physiologic or
cultural differences (or both) remains unclear.
Available historical data about drug resistance
rates in Taiwan are not directly comparable because
of different sampling methods and because different
susceptibility testing methods have been applied in
various hospital settings over time. Isoniazid was
introduced for TB treatment in 1952. From 1990 to
2002, primary resistance to isoniazid ranged from
4.7% to 12%. The acquired resistance rate (25–63%) to
isoniazid was significantly higher than the primary
resistance rate. Chemotherapy regimens, which include
rifampin, have been widely used in Taiwan since 1978.
The primary resistance rate to rifampin has gradually
increased from 0.7% to 5.9% during the last decade.
The acquired resistance rate (17–46%) to rifampin
was significantly higher than the primary resistance
rate. The primary resistance rate to ethambutol was
1–6% and that to streptomycin was 4–11% from 1990
to 2002. The overall rates of primary MDR-TB were
within 1–3% in the last decade. However, the rates
(15–46%) of acquired resistance of MDR-TB were sig-
nificantly higher than those of primary resistance
[5,23–29]. Fluoroquinolones were introduced in Taiwan
in 1986 for the treatment of mycobacterial and other
bacterial diseases. Yu et al found in 1994–5 that primary
resistance to ofloxacin was 0.8% and that acquired
resistance to ofloxacin was 87.5% [30].
The Taiwan Center for Disease Control initiated the
Taiwan Surveillance of Drug Resistance in Tubercu-
losis program in 2003. Since clinical data were not
available, only combined (primary plus acquired) drug
resistance rates were analyzed. That survey showed
that the combined drug resistance rates were 9.5% 
to isoniazid, 6.4% to rifampin, 5.8% to ethambutol,
9.6% to streptomycin, 20.0% to any drug, and 4.0% to
MDR-TB [31]. In the third global drug resistance sur-
veillance report, the combined drug resistance was
6.6% to isoniazid, 2.2% to rifampin, 1.3% to ethambutol,
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6.1% to streptomycin, 10.4% to any drug, and 1.7% to
MDR-TB [3].
In our study, the combined resistance rates to the
tested first-line agents were as follows: 3.2% to isoni-
azid, 7.8% to rifampin, 5.8% to ethambutol, 2.6% to
streptomycin, 12.3% to any drug, and 1.9% to MDR-
TB. The combined resistance rates to isoniazid and
streptomycin were lower than both average levels in
Taiwan and the global combined drug resistance rate.
The combined resistance rate to ethambutol was sim-
ilar to the average level in Taiwan and higher than
the global combined drug resistance rate. However,
the combined resistance rate to rifampin was higher
than both the average level in Taiwan and the global
combined drug resistance rate. The combined resist-
ance rate to at least any one of four first-line drugs
and MDR-TB was lower than the average level in
Taiwan and higher than the global combined drug
resistance rate. Differences in the bacteriology results
noted in different studies might reflect local variations
in disease.
According to the most recent WHO annual report,
the treatment success rate in the 2003 cohort was 82%
globally [6]. Among the 14,486 TB patients who
received anti-TB treatment in 2001 in Taiwan, 73.3%
completed a full course of treatment, 20.1% died during
treatment (not all related to TB), 5.6% defaulted treat-
ment, and, in 0.36%, treatment failed [12]. Comparison
of the treatment outcomes between our study and the
TB annual report (Taiwan) revealed that the propor-
tion of patients whose treatment was successful had
increased, while the proportions who died, defaulted
treatment or in whom treatment failed, had decreased.
Much of the persistence of the TB epidemic may
be attributable to the failure to comply with treat-
ment regimens and the lack of follow-up. The 3.9%
rate of treatment default in this study is unacceptably
high. These failures may be partially explained as being
due to beliefs and attitudes toward TB infection by
Taiwanese. The perception of social stigma placed on
the infected individual and his/her family may lead
patients to avoid or cease treatment. The inability 
to identify those patients likely to abandon therapy
emphasizes the need to treat all patients with a directly
observed therapy short-course (DOTS). As these cases
have been identified as the most significant source of
infection in a community, efforts should be immedi-
ately refocused on improving the cure rates in these
groups.
In summary, we have described the contemporary
clinical presentation, bacteriological results and treat-
ment outcomes of persons with pulmonary TB in 
an Asian city. This retrospective study evaluated the
epidemiology of pulmonary TB from a hospital-based
survey in southern Taiwan during the period from
August 1, 2003 to July 31, 2006. The results may help
identify local variations in disease and improve the
effectiveness of TB infection control programs.
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